Anavex Life Sciences Corp. · NASDAQ:AVXL

Anavex Life Sciences — Investor Presentation (October 2019)

38 slides from Anavex Life Sciences's investor presentation, October 2019

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Corporate Presentation Christopher U Missling, PhD | President & CEO Nasdaq: AVXL | October 2019

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    SAFE HARBOR This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “b

  3. Slide 3: Anavex Life Sciences Portfolio Compounds

    Slide 3: Anavex Life Sciences Portfolio Compounds

    Anavex Life Sciences Portfolio Compounds CANDIDATE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALZHEIMER’S DISEASE ANAVEX®2-73 PARKINSON’S DISEASE DEMENTIA *RETT SYNDROME *INFANTILE SPASMS FRAGILE X ANGELMAN’S *FRONT. DEMENTIA (FTD) ANAVEX®3-71 (AF710B) ALZHEIMER’S DISEASE PARKINSON’S DISEASE DEPRESSION ANA

  4. Slide 4: New Therapeutic Strategy to Treat CNS Disorders

    Slide 4: New Therapeutic Strategy to Treat CNS Disorders

    New Therapeutic Strategy to Treat CNS Disorders • Anavex utilizes genomic biomarkers in precision medicine to treat severe and devastating neurological disorders • Anavex is focusing on rare diseases with no available therapy (Rett syndrome) and high risk CNS patient populations (Alzheimer’s disease

  5. Slide 5: Anavex at a Glance

    Slide 5: Anavex at a Glance

    Anavex at a Glance APPROACH Applying precision medicine to CNS disorders Patient selection based on genomic screening and biomarkers MECHANISM SIGMAR1 restoring cellular homeostasis FOCUS Finding effective treatments for neurodevelopmental and neurodegenerative diseases $ LARGE MARKETS Addressing un

  6. Slide 6: Overview ANAVEX 2-73 Precision Medicine Clinical Trials

    Slide 6: Overview ANAVEX 2-73 Precision Medicine Clinical Trials

    Overview ANAVEX®2-73 Precision Medicine Clinical Trials PHASE 2 PK and Safety & Efficacy (AVATAR) RETT SYNDROME** 7 21+33 ANAVEX®2-73-RS-001 STUDY (NCT03758924)* and ANAVEX®2-73-RS-002 AVATAR STUDY (NCT03941444)* Pediatric Safety & Efficacy (EXCELLENCE) RETT SYNDROME** 12 69 ANAVEX®2-73-RS-003 EXCEL

  7. Slide 7: U.S. ANAVEX 2-73-RS-001 Trial (NCT03758924)

    Slide 7: U.S. ANAVEX 2-73-RS-001 Trial (NCT03758924)

    U.S. ANAVEX®2-73-RS-001 Trial (NCT03758924) • Phase 2, safety, tolerability, efficacy • Females > 18 years, classic RTT w/MECP2 mutation • Efficacy: • Primary*: Global severity (RSBQ, CGI-I) • Secondary: Behavior (ADAMS), Sleep (CSHQ), VAS (top caregiver concerns), Seizure diary • Response Biomarker

  8. Slide 8: Efficacy: RSBQ & CGI-I Improved During Trial

    Slide 8: Efficacy: RSBQ & CGI-I Improved During Trial

    Efficacy: RSBQ & CGI-I Improved During Trial RSBQ Total & CGI-I Correlated at Week 7 5 4 4 CGI-I Week 7 3 3 2 2 1 1 0 0 10 20 30 40 50 60 RSBQ Total Week 7 Spearman’s rho = 0.956, p = 0.003 8

  9. Slide 9: Biomarkers: Plasma Glutamate & CSHQ (Sleep) Total Correlated at Week 7

    Slide 9: Biomarkers: Plasma Glutamate & CSHQ (Sleep) Total Correlated at Week 7

    Biomarkers: Plasma Glutamate & CSHQ (Sleep) Total Correlated at Week 7 40 CSHQ (Sleep) Total Week 7 35 30 25 20 15 10 10.00 15.00 20.00 25.00 30.00 35.00 40.00 Glutamate µmol/L Week 7 Spearman’s rho = 0.943, p = 0.005 9

  10. Slide 10: Mechanism of Action

    Slide 10: Mechanism of Action

    Mechanism of Action ANAVEX®2-73 Activation of Sigma-1 Receptor Effects on Neurons & Microglia: Glutamate as Efficacy Biomarker Glutaminase Glutaminase Glutamate Glutamate Glutamate 10

  11. Slide 11: Conclusions on ANAVEX 2-73 in Rett Syndrome

    Slide 11: Conclusions on ANAVEX 2-73 in Rett Syndrome

    Conclusions on ANAVEX®2-73 in Rett Syndrome • Despite the small sample size, Preliminary data demonstrates Encouraging Safety and Efficacy Signal on both Caregiver- & Clinician-based measures of Severity • Correlations with Key Biomarker related to disease Pathogenesis • High Level of Significance:

  12. Slide 12: Catalysts to Drive Value

    Slide 12: Catalysts to Drive Value

    Catalysts to Drive Value The company is well positioned to achieve key clinical readouts Phase 2b/3 clinical trial in Alzheimer’s disease – ongoing Phase 2 clinical trial in Parkinson’s disease dementia (PDD) – ongoing Initiate Phase 2 clinical trial in Rett syndrome (RTT) Oral presentation at AAIC

  13. Slide 13: SIGMAR1 Activation Modulates Multiple Aspects of Neurodegenerative Processes

    Slide 13: SIGMAR1 Activation Modulates Multiple Aspects of Neurodegenerative Processes

    SIGMAR1 Activation has been Shown to Modulate Multiple Aspects of Neurodegenerative Processes Sigma-1 receptor agonists ANAVEX®2-73 alleviates Tau Sigma-1 receptor agonists have been shown to restore pathology in neurodegenerative have a neuroprotective effect neuronal functions in disease models in

  14. Slide 14: Autophagy as Key Protein Clearance Process

    Slide 14: Autophagy as Key Protein Clearance Process

    Autophagy as Key Protein Clearance Process: New Pharmacological Target in Neurodegeneration – achieved through SIGMAR1 Activation Sigma-1 receptor activation by ANAVEX2-73 enhances autophagy in C. elegans p ≤ 0.001 14

  15. Slide 15: Genetic SIGMAR1 Variations Linked to Neurological Disorders

    Slide 15: Genetic SIGMAR1 Variations Linked to Neurological Disorders

    Genetic SIGMAR1 Variations Linked to Neurological Disorders The SIGMAR1 receptor is an integral • SIGMAR1 null mice display muscle membrane protein involved in cellular weakness, axonal degeneration homeostasis which targets restoration and motor neuron loss1 of neuroplasticity and cellular stress r

  16. Slide 16: Quantitative PET Scan: Dose-dependent Target Engagement with Sigma-1 Receptor

    Slide 16: Quantitative PET Scan: Dose-dependent Target Engagement with Sigma-1 Receptor

    Quantitative PET Scan: Dose-dependent ANAVEX®2-73 Target Engagement with the Sigma-1 Receptor 2D [18F]FTC-146-PET imaging of ANAVEX®2-73 0 mg /kg 1 mg/kg 10 mg/kg 30 mg/kg 100 Percent Sigma-1 Receptor 80 Sigma-1 receptor target occupancy Occupancy 60 study with 40 quantitative PET 20 scan of ANAVEX®

  17. Slide 17: Patients Improvement Correlates with ANAVEX 2-73 and SIGMAR1 RNA Expression

    Slide 17: Patients Improvement Correlates with ANAVEX 2-73 and SIGMAR1 RNA Expression

    Patients Improvement Correlates with ANAVEX®2-73 and SIGMAR1 RNA Expression Activities of Daily Living (ADCS-ADL)* Slope from Baseline to Week 57 p=0.015 ANAVEX®2-73 SIGMAR1 RNA expression (TPM) positive response in functional (ADCS- ADL) outcomes in Alzheimer’s disease patients corelate with SIGMAR

  18. Slide 18: Significant Relationship between ANAVEX 2-73 Concentration and Patients Response

    Slide 18: Significant Relationship between ANAVEX 2-73 Concentration and Patients Response

    Significant Relationship between ANAVEX®2-73 Concentration and Patients Response Activities of Daily Living (ADCS-ADL)* ADCS-ADL (Delta from Baseline to Week 57) p=0.03 • High Concentration of ANAVEX®2-73 => High Delta ADCS-ADL (improved response) • # Plasma concentration of ANAVEX®2-73 is correlate

  19. Slide 19: Higher Concentration Maintain ADCS-ADL Performance vs Lower Concentration

    Slide 19: Higher Concentration Maintain ADCS-ADL Performance vs Lower Concentration

    Patients Treated with Higher ANAVEX®2-73 Concentration Maintain ADCS-ADL* Performance vs Lower Concentration Cohort High Concentration cohort shows 88 % difference to low concentration cohort • High plasma concentration of ANAVEX®2-73 [>4.0 ng/ml] is correlated with the clinically administered dose

  20. Slide 20: Higher Concentration Show Higher MMSE Performance

    Slide 20: Higher Concentration Show Higher MMSE Performance

    Patients Treated with Higher ANAVEX®2-73 Concentration Show Higher MMSE* Performance Compared to Lower Concentration High Concentration cohort shows 64 % less decline than low concentration cohort • High plasma concentration of ANAVEX®2-73 [>4.0 ng/ml] is correlated with the clinically (p < 0.0008)

  21. Slide 21: Precision Medicine

    Slide 21: Precision Medicine

    Precision Medicine

  22. Slide 22: Precision Medicine

    Slide 22: Precision Medicine

    Precision Medicine PHARMACOLOGY + GENOMIC = Patient Selection with Biomarker PHARMACOGENOMICS Increases Probability of Success 76% The ideal pharmacogenomics test will be able to determine: 55% • Potential for a medication to be 46% effective – for this person • The best dose of a medication – 28% f

  23. Slide 23: Identification of Gene Signature from ANAVEX 2-73-Treated Patients

    Slide 23: Identification of Gene Signature from ANAVEX 2-73-Treated Patients

    Identification of Gene “Signature” from ANAVEX®2-73-Treated Patients PRECISION MEDICINE • Genomic signature (WT SIGMAR1 gene) strongest responders to ANAVEX®2-73 • This genomic “biomarker” is drug specific, not indication specific, so it applies to all indications treated with ANAVEX®2-73 23

  24. Slide 24: SIGMAR1 Gene Plays a Role in Protein Trafficking

    Slide 24: SIGMAR1 Gene Plays a Role in Protein Trafficking

    SIGMAR1 Gene Plays a Role in Protein Trafficking Lumenal side Transmembrane region SIGMAR1 WT rs1800866 variant structure impairs protein trafficking Cytosolic side • Majority of the population (~80%) carries SIGMAR1 WT • Majority of patients (~80%) are expected to benefit from SIGMAR1 activation wi

  25. Slide 25: SIGMAR1 WT Gene Associated with Improved Response

    Slide 25: SIGMAR1 WT Gene Associated with Improved Response

    SIGMAR1 WT Gene Associated with Improved Response … … and validated at 148 weeks Delta MMSE Delta ADCS-ADL (Week 57 from Baseline) (Week 57 from Baseline) p=0.023 p=0.048 SIGMAR1 SIGMAR1 WT SIGMAR1 SIGMAR1 WT Pro2 variant (n=15) Pro2 variant (n=15) (rs1800866) (rs1800866) (n=5) (n=5) Source: H Hampe

  26. Slide 26: Clinical Studies

    Slide 26: Clinical Studies

    Clinical Studies: • Rett Syndrome (RTT) • Parkinson’s Disease Dementia (PDD) • Alzheimer’s Disease (AD)

  27. Slide 27: Pipeline Addresses both Rare and Large Indications

    Slide 27: Pipeline Addresses both Rare and Large Indications

    Pipeline Addresses both Rare and Large Indications Anavex pipeline and precision genetic medicine approach address unmet Alzheimer’s Disease (AD) needs of neurodevelopmental and neurodegenerative diseases ~5,700,000 patients1 Parkinson’s Disease (PD) ~1,000,000 patients2 Rett Syndrome (RTT) ~11,000

  28. Slide 28: ANAVEX 2-73 Phase 2 Rett Syndrome Study N=21

    Slide 28: ANAVEX 2-73 Phase 2 Rett Syndrome Study N=21

    ANAVEX®2-73 Phase 2 Rett Syndrome Study N=21 * 7 RTT pa<ent popula<on ANAVEX®2-73 Primary and Secondary Endpoints Active dose# • PK, Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age >18 • Seizure activity Randomiza1on • DNA and

  29. Slide 29: ANAVEX 2-73 Phase 2 Rett Syndrome AVATAR Study N=33

    Slide 29: ANAVEX 2-73 Phase 2 Rett Syndrome AVATAR Study N=33

    ANAVEX®2-73 Phase 2 Rett Syndrome AVATAR Study N=33 * 7 RTT pa<ent popula<on ANAVEX®2-73 Primary and Secondary Endpoints Active dose# • Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age >18 • Seizure activity Randomiza1on • DNA

  30. Slide 30: ANAVEX 2-73-RS-003 Rett Syndrome EXCELLENCE Study N=69

    Slide 30: ANAVEX 2-73-RS-003 Rett Syndrome EXCELLENCE Study N=69

    ANAVEX®2-73-RS-003 Rett Syndrome EXCELLENCE Study N=69 12 RTT pa<ent popula<on ANAVEX®2-73 Primary and Secondary Endpoints Active dose# • Safety and tolerability of ANAVEX®2-73 • Diagnosis of • Behavioral symptoms confirmed RTT • Sleep function • Patients age 5-18 • Seizure activity Randomiza1on • D

  31. Slide 31: ANAVEX 2-73 Phase 2 Parkinson's Disease Dementia Study N=120

    Slide 31: ANAVEX 2-73 Phase 2 Parkinson's Disease Dementia Study N=120

    ANAVEX®2-73 Phase 2 Parkinson’s Disease Dementia Study N=120 14 PDD pa<ent popula<on Primary Endpoints • CDR Continuity of Attention ANAVEX®2-73 • Safety and tolerability of • Diagnosis of High dose# ANAVEX®2-73 probable Parkinson’s disease dementia Key Secondary Endpoints • MDS-UPDRS (PDD) • Sleep

  32. Slide 32: Primary Endpoint CDR Continuity of Attention of PDD Ph2 Study

    Slide 32: Primary Endpoint CDR Continuity of Attention of PDD Ph2 Study

    Primary Endpoint ‘CDR Continuity of Attention’ of PDD ANAVEX®2-73 Ph2 Study: Confirmed Beneficial Effect in Previous Ph2a AD Study Identification (IDN) in Cogstate battery assessed in ANAVEX®2-73 Ph2a AD Study comparable to CDR Continuity of Attention (choice reaction time paradigm) CDR ba;ery Cogst

  33. Slide 33: ANAVEX 2-73 Ph2 AD Study - Cogstate IDN Improves within Weeks

    Slide 33: ANAVEX 2-73 Ph2 AD Study - Cogstate IDN Improves within Weeks

    ANAVEX®2-73 Ph2 AD Study - Cogstate IDN Improves within Weeks Cogstate IDN from Baseline Average Delta Reaction time (ms) ANAVEX®2-73 Cogstate IDN Weeks from Baseline Bars: Standard Error 33

  34. Slide 34: Cogstate IDN: ANAVEX 2-73 Ph2a AD Patients vs Standard of Care

    Slide 34: Cogstate IDN: ANAVEX 2-73 Ph2a AD Patients vs Standard of Care

    Cogstate IDN: ANAVEX®2-73 Ph2a AD Patients Improve within Weeks vs Standard of Care AD Patients AIBL-ROCS-AD* cohort as standard of care comparator Average Delta Reaction time (ms) SoC (AIBL- ANAVEX® Baseline data: Cogstate IDN ROCS-AD) 2-73 Participants (n) 35 32 MMSE (mean) 21.2 21.0 (p<0.01) ANAV

  35. Slide 35: ANAVEX 2-73 Phase 2b/3 Alzheimer's Disease Study N=450

    Slide 35: ANAVEX 2-73 Phase 2b/3 Alzheimer's Disease Study N=450

    ANAVEX®2-73 Phase 2b/3 Alzheimer's Disease Study N=450 48 Primary Endpoints Early AD pa<ent popula<on • ADAS-Cog ANAVEX®2-73 • ADCS-ADL High dose# • Confirmed amyloid • Safety and tolerability of pathophysiology ANAVEX®2-73 (CSF/amyloid PET) Key Secondary Endpoints • Patients aged 60 to • CDR-SB 85

  36. Slide 36: Investment Highlights

    Slide 36: Investment Highlights

    Investment Highlights • Pursuing Large Markets By Applying Precision Medicine to Develop Treatments For Neurodegenerative and Neurodevelopmental Diseases With High Unmet Needs – Novel genomic biomarker-driven programs to treat small patient populations such as Rett syndrome* as well as major public

  37. Slide 37: Anavex Life Sciences Expertise

    Slide 37: Anavex Life Sciences Expertise

    Anavex Life Sciences Expertise Management Team Christopher U. Missling PhD - President & CEO Walter E Kaufmann, MD - Chief Medical Officer Stephan Toutain, MS, MBA – Chief Operating Officer Emmanuel O Fadiran, RPh, PhD - SVP of Regulatory Affairs Daniel Klamer, PhD - VP of Business Development & Sci

  38. Slide 38: Contact Us

    Slide 38: Contact Us

    Contact Us Corporate Office Anavex®Life Sciences Corp. 51 West 52nd Street, 7th floor New York, NY 10019 1-844-689-3939 Shareholder & Media Relations ir@anavex.com www.anavex.com NASDAQ: AVXL 38

Source: Internet Archive copy of anavex.com

More decks from Anavex Life Sciences Corp.

All 35 Anavex Life Sciences decks